<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Previously, puerarin has been reported to be effective in preventing an HFD induced obese phenotype by ameliorating impaired glucose and lipid metabolism [
 <xref rid="pone.0218490.ref038" ref-type="bibr" class="xref">38</xref>], increasing the energy metabolism in skeletal muscles of obese rodents [
 <xref rid="pone.0218490.ref039" ref-type="bibr" class="xref">39</xref>], inhibiting oxidative stress [
 <xref rid="pone.0218490.ref037" ref-type="bibr" class="xref">37</xref>], suppressing inflammation [
 <xref rid="pone.0218490.ref002" ref-type="bibr" class="xref">2</xref>] as well as improving insulin signaling [
 <xref rid="pone.0218490.ref040" ref-type="bibr" class="xref">40</xref>]. However, whether such a broad effect of puerarin on anti-obesity and the related complications is through the regulation of gut microbiota is not known.
</p>
